Loading...

Replimune Group

MUN:7R8
Snowflake Description

Excellent balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
7R8
MUN
$366M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The last earnings update was 52 days ago. More info.


Add to Portfolio Compare Print Invest
7R8 Share Price and Events
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

7R8 Value

 Is Replimune Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Replimune Group. This is due to cash flow or dividend data being unavailable. The share price is €12.55.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Replimune Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Replimune Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
MUN:7R8 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in USD $-5.26
NasdaqGS:REPL Share Price ** NasdaqGS (2018-07-24) in USD $11.61
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 29.7x
Germany Market PE Ratio Median Figure of 407 Publicly-Listed Companies 18.16x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Replimune Group.

MUN:7R8 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:REPL Share Price ÷ EPS (both in USD)

= 11.61 ÷ -5.26

-2.21x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Replimune Group is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Replimune Group is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Replimune Group's expected growth come at a high price?
Raw Data
MUN:7R8 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.21x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-22.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 16 Publicly-Listed Biotechs Companies 1.65x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.38x

*Line of best fit is calculated by linear regression .

MUN:7R8 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= -2.21x ÷ -22.5%

0.1x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Replimune Group is loss making, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Replimune Group's assets?
Raw Data
MUN:7R8 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in USD $-7.73
NasdaqGS:REPL Share Price * NasdaqGS (2018-07-24) in USD $11.61
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.4x
Germany Market PB Ratio Median Figure of 547 Publicly-Listed Companies 1.9x
MUN:7R8 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:REPL Share Price ÷ Book Value per Share (both in USD)

= 11.61 ÷ -7.73

-1.5x

* Primary Listing of Replimune Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Replimune Group has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
X
Value checks
We assess Replimune Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Replimune Group has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

7R8 Future Performance

 How is Replimune Group expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-22.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Replimune Group expected to grow at an attractive rate?
  • Unable to compare Replimune Group's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Replimune Group's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Replimune Group's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
MUN:7R8 Future Growth Rates Data Sources
Data Point Source Value (per year)
MUN:7R8 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -22.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 49.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 22.7%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.9%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
MUN:7R8 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
MUN:7R8 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-03-31 18 -50 -74 1
2022-03-31 3 -46 -77 1
2021-03-31 0 -41 -55 2
2020-03-31 0 -43 -44 3
2019-03-31 0 -28 -32 3
MUN:7R8 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-06-30 -17 -26
2018-03-31 -16 -20
2017-12-31 -15 -17
2017-03-31 -7 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Replimune Group is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Replimune Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
MUN:7R8 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Replimune Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

MUN:7R8 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-03-31 -1.80 -1.80 -1.80 1.00
2022-03-31 -2.06 -2.06 -2.06 1.00
2021-03-31 -1.47 -1.25 -1.71 3.00
2020-03-31 -1.24 -1.09 -1.32 3.00
2019-03-31 -1.13 -0.93 -1.29 3.00
MUN:7R8 Past Financials Data
Date (Data in USD Millions) EPS *
2018-06-30 -5.26
2018-03-31 -3.96
2017-12-31 -3.34
2017-03-31 -1.55

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Replimune Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Replimune Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Replimune Group has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

7R8 Past Performance

  How has Replimune Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Replimune Group's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Replimune Group does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Replimune Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Replimune Group's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Replimune Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Replimune Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

MUN:7R8 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 -26.19 6.77 12.92
2018-03-31 -19.70 5.71 11.25
2017-12-31 -16.72 4.39 9.34
2017-03-31 -7.70 2.71 5.49

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Replimune Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Replimune Group has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Replimune Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Replimune Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Replimune Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

7R8 Health

 How is Replimune Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Replimune Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Replimune Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Replimune Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Replimune Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Replimune Group has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Replimune Group Company Filings, last reported 3 months ago.

MUN:7R8 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 54.75 0.00 52.03
2018-03-31 59.94 0.00 61.55
2017-12-31 65.77 0.00 65.03
2017-03-31 20.76 0.00 20.59
  • Replimune Group has no debt.
  • Replimune Group has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Replimune Group has sufficient cash runway for more than 3 years based on current financial obligations.
  • Unable to confirm if Replimune Group has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Replimune Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Replimune Group has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

7R8 Dividends

 What is Replimune Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Replimune Group dividends.
If you bought €2,000 of Replimune Group shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Replimune Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Replimune Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
MUN:7R8 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 322 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

MUN:7R8 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-03-31
2022-03-31
2021-03-31
2020-03-31
2019-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Replimune Group has not reported any payouts.
  • Unable to verify if Replimune Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Replimune Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Replimune Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Replimune Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Replimune Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Replimune Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

7R8 Management

 What is the CEO of Replimune Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rob Coffin, image provided by Google.
Rob Coffin
AGE 53
TENURE AS CEO 3.8 years
CEO Bio

Dr. Robert Coffin, Ph.D. also known as Rob, co-founded Replimune Ltd and serves as its Chief Executive Officer. Dr. Coffin serves as President, Chief Executive Officer and Director at Replimune Group, Inc since 2015. He Co-Founded BioVex Group, Inc. and served as its Chief Scientific Officer since 1999. Dr. Coffin was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC) and oversaw all research and clinical development including bringing T-VEC through to two pivotal phase 3 studies in melanoma and head & neck cancer under SPA before sale of BioVex to Amgen in 2011 where he became Vice President of Global Development until 2013. Dr. Coffin was a founding scientist and Lecturer in Virology and Gene Therapy at University College London and Honorary Senior Lecturer at The Institute of Child Health. He is an expert in the application of virus-based technology to the development of therapeutic products and vaccines, has authored more than 50 scientific papers and is a named inventor on all of the patents filed in BioVex name. He served as a Director of Replimune Ltd until July 10, 2017. He served as Director of BioVex Group, Inc. Dr. Coffin received his PhD in 1991 from Imperial College, London, following which he moved to University College London where he ultimately led the research group.

CEO Compensation
  • Insufficient data for Rob to compare compensation growth.
  • Insufficient data for Rob to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Replimune Group management team in years:

3
Average Tenure
53
Average Age
  • The tenure for the Replimune Group management team is about average.
Management Team

Philip Astley-Sparke

TITLE
Executive Chairman
AGE
47

Rob Coffin

TITLE
President
AGE
53
TENURE
3.8 yrs

Colin Love

TITLE
Chief Operating Officer
AGE
60
TENURE
3 yrs

Stephen Gorgol

TITLE
Chief Accounting Officer

Pamela Esposito

TITLE
Chief Business Officer
AGE
44
TENURE
2.9 yrs

Howard Kaufman

TITLE
Chief Medical Officer
AGE
57
TENURE
1.1 yrs
Board of Directors Tenure

Average tenure and age of the Replimune Group board of directors in years:

3.1
Average Tenure
53
Average Age
  • The tenure for the Replimune Group board of directors is about average.
Board of Directors

Philip Astley-Sparke

TITLE
Executive Chairman
AGE
47
TENURE
3.8 yrs

Rob Coffin

TITLE
President
AGE
53
TENURE
3.8 yrs

Kapil Dhingra

TITLE
Director
COMPENSATION
$200K
AGE
59
TENURE
1.3 yrs

Jason Rhodes

TITLE
Director
AGE
48
TENURE
3.1 yrs

Joe Slattery

TITLE
Director
AGE
53
TENURE
1 yrs

Dieter Weinand

TITLE
Director
AGE
58
TENURE
0.3 yrs

Hy Levitsky

TITLE
Director
AGE
60
TENURE
0.4 yrs

Sander Slootweg

TITLE
Director
AGE
50
TENURE
3.8 yrs

Otello Stampacchia

TITLE
Director
AGE
44
TENURE
3.4 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Replimune Group insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Start End Shares Value (USD)
26. Jul 18 Buy Bain Capital, LP Company 24. Jul 18 24. Jul 18 500,000 $7,500,000.00
26. Jul 18 Buy Forbion Capital Partners Company 24. Jul 18 24. Jul 18 133,333 $1,999,995.00
26. Jul 18 Buy Joseph Slattery Individual 24. Jul 18 24. Jul 18 6,667 $100,005.00
25. Jul 18 Buy Omega Fund Management, LLC Company 24. Jul 18 24. Jul 18 266,667 $4,000,005.00
X
Management checks
We assess Replimune Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Replimune Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

7R8 News

External News
Loading...
Simply Wall St News

7R8 Company Info

Map
Description

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Details
Name: Replimune Group, Inc.
7R8
Exchange: MUN
Founded: 2015
$318,933,977
31,553,672
Website: http://www.replimune.com
Address: Replimune Group, Inc.
18 Commerce Way,
Woburn,
Massachusetts, 01801,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS REPL Common Stock Nasdaq Global Select US USD 20. Jul 2018
DB 7R8 Common Stock Deutsche Boerse AG DE EUR 20. Jul 2018
MUN 7R8 Common Stock Boerse Muenchen DE EUR 20. Jul 2018
Number of employees
Current staff
Staff numbers
44
Replimune Group employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/10/21 18:45
End of day share price update: 2018/07/24 00:00
Last estimates confirmation: 2018/09/06
Last earnings filing: 2018/08/30
Last earnings reported: 2018/06/30
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.